One pilot randomized cross-over trial showed that sera from subjects with type 1 diabetes treated with glargine stimulated the growth of human breast carcinoma cells to a greater extent than sera from the same patients during treatment with NPH human insulin [89]. This evidence concerns the gene INS and breast carcinoma.